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Abstract
Objective: To assess the in-hospital and short-term outcome differences between males
and females who underwent high-risk PCI with mechanical circulatory support (MCS).
Background: Sex differences have been noted in several percutaneous coronary
intervention (PCI) series with females less likely to be referred for PCI due increased
risk of adverse events. However, data on sex differences in utilization and outcomes
of high-risk PCI with MCS is scarce.
Methods: Using the cVAD Registry, we identified 1,053 high-risk patients who
underwent PCI with MCS using Impella 2.5 or Impella CP. Patients with cardiogenic
shock were excluded. A total of 792 (75.21%) males and 261 (24.79%) females were
included in the analysis with median follow-up of 81.5 days.
Results: Females were more likely to be African American, older (72.05 ± 11.66
vs. 68.87 ± 11.17, p < .001), have a higher prevalence of diabetes (59.30 vs. 49.04%,
p = .005), renal insufficiency (35.41 vs. 27.39%, p = .018), and peripheral vascular dis-
ease (31.89 vs. 25.39%, p of .05). Women had a higher mean STS score (8.21 ± 8.21
vs. 5.04 ± 5.97, p < .001) and lower cardiac output on presentation (3.64 ± 1.30
vs. 4.63 ± 1.49, p < .001). Although women had more comorbidities, there was no
difference in in-hospital mortality, stroke, MI or need for recurrent revascularization
compared to males. Females were more likely to have multivessel revascularization
than males. Ejection fraction improved in both males and females at the time of dis-
charge (26.59 to 31.40% and 30.75 to 36.05%, respectively, p < .0001). However,
Abbreviations: AKI, acute kidney injury; BSA, body surface area; CHIP, complex high-risk indicated patients; CT scan, computed tomography scan; cVAD registry, catheter based ventricular assist
device registry; MACCE, major adverse cardiovascular and cerebrovascular events; MCS, mechanical circulatory support; MI, myocardial infarction; PA, pulmonary artery; PCI, percutaneous
coronary intervention; SD, standard deviation; STS Risk Score, society of thoracic surgery risk score.
M Chadi Alraies and Amir Kaki contributed equally.
Received: 7 February 2019 Revised: 12 July 2019 Accepted: 17 September 2019
DOI: 10.1002/ccd.28509
536 © 2019 Wiley Periodicals, Inc. Catheter Cardiovasc Interv. 2020;96:536–544.wileyonlinelibrary.com/journal/ccd
females had higher rate of bleeding requiring transfusion compared with males (9.58
vs. 5.30%, p = .019).
Conclusion: Female patients undergoing high PCI were older and had more com-
orbidities but had similar outcomes compared to males.
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1 | INTRODUCTION
Ischemic heart disease continues to be the leading cause of morbidity
and mortality for both males and females.1 Patients with complex high-
risk symptomatic coronary artery disease are commonly encountered in
current practice. Complex high-risk indicated patients or as also known
as (CHIP) is defined by the presence of one of the following: patients
undergoing percutaneous coronary intervention (PCI) of unprotected
left main, last patent coronary conduit, vessel supplying a large myocar-
dial territory with severely depressed ejection fraction (EF), or PCI of a
vessel supplying a large territory in the setting of cardiogenic shock.2
CHIP cases also include severe coronary calcification and patients who
are poor surgical candidates due to their comorbidities. In such cases,
PCI with adequate mechanical circulatory support has become an
important part of the revascularization strategy decision-making.
Indeed, protected PCI using percutaneous mechanical circulatory sup-
port has been demonstrated to be equally safe and effective as coro-
nary artery bypass grafting.3 Current guidelines recommend elective
insertion of hemodynamic support devices in selected patients under-
going high-risk coronary interventions.2 Further, the elective use of
Impella 2.5 and Impella CP (Abiomed Inc., Danvers, MA) devices in
patients having high-risk PCI have been shown to be safe and effective,
and also provide a left ventricular unloading effect.4–7
Compared with males, females with acute coronary syndromes
have higher unadjusted mortality, less use of guideline-recommended
therapies and less access to revascularization therapies.8–10 Further-
more, utilization of mechanical circulatory support (MCS) in the set-
ting of cardiogenic shock is used less frequently in females compared
to males.11,12 Despite a higher risk-factor profile in females, there is a
paucity of sex-specific safety, effectiveness, and outcomes data for
mechanical support for high-risk PCI. Therefore, we sought to evalu-
ate the sex differences in outcomes of mechanical circulatory support
with Impella in patients undergoing high-risk PCI.
2 | MATERIALS AND METHODS
2.1 | Study population
Using the cVAD Registry, we identified a total of 1,053 complex high-
risk indicated patients who underwent PCI with MCS using Impella
2.5 or Impella CP between June 2007 and June 2015. Eligible patients
were those who underwent elective or urgent PCI with the aid of
hemodynamic support with an Impella 2.5 or Impella CP, placed prior
to the start of PCI. Patients in cardiogenic shock were excluded from
this analysis. The design and methods of cVAD registry (the catheter
based ventricular assist device registry) have been previously
described.13 The cVAD Registry is an expansion of the USpella Regis-
try to European sites during the period 2015–2016 and Japanese sites
expected after 2019.14 In brief, the cVAD Registry is an ongoing mul-
ticenter voluntary registry open to centers in the United States,
Canada, and Europe. The cVAD Registry was designed by an Execu-
tive Steering Committee that oversees its ongoing conduct. The regis-
try protocol was reviewed and approved by the Institutional Review
Board at each participating site. Sites are expected to report all con-
secutive Impella cases without preselection of indication or patients.
Patients who were identified as having received an Impella device in a
separate commercial database (IQ) were expected to be reported in
the cVAD Registry database; otherwise sites were notified of the obli-
gation to enter and report the cases to ensure consecutiveness.
2.2 | Outcomes
Our study looked at cardiac, stroke, renal, and bleeding outcomes in
the cVAD Registry. Acute myocardial infarction was defined by detec-
tion of rise and/or fall of cardiac biomarkers (preferably troponin) with
at least one value above the 99th percentile of the upper reference
limit together with evidence of myocardial ischemia with at least one of
the following: symptoms of ischemia, ECG changes indicative of new
ischemia (new ST-T changes or new left bundle branch block [LBBB]),
development of pathological Q waves in the ECG, or imaging evidence
of new loss of viable myocardium or new regional wall motion abnor-
mality. Revascularization was defined as any repeat revascularization
based on the presence of ischemia, defined either as recurrent angina
or equivalent and/or a positive functional study that involves: (a) the
target lesion (the originally treated segments; for stented lesions this
includes an area 5 mm proximal or distal to the stented segment), or
(b) target vessel (all coronary segments in the same epicardial artery as
the treated lesion if that segment may have been involved during pas-
sage of the coronary guidewire or any treatment device), or
(c) nontarget vessels. This intervention could be either percutaneous or
surgical bypass. Valve injury was defined as injury to the aortic valve
regardless of the cause and assessed by Doppler echocardiography
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versus baseline or during autopsy. Aortic regurgitation was assessed by
transthoracic echocardiographic measurements and defined as ≥ Grade
2 or an increase in aortic regurgitation by more than one assessment
level on a 4-point scale.
Stroke is defined as an ischemic or hemorrhagic cerebrovascular
accident that persists beyond 24 hr or less than 24 hr associated with
infarction on an imaging study. Major adverse cardiovascular and
cerebrovascular events (MACCE) is the rate of the following events
occurring after the intervention until 30 days; death (all-cause mortal-
ity), cerebrovascular accident, hospitalization due to heart failure,
documented nonfatal myocardial infarction, or repeat revasculariza-
tion by coronary stenting or oronary artery bypass graft surgery
(CABG). Acute renal dysfunction is defined as abnormal kidney func-
tion requiring dialysis (including hemofiltration) in patients who did
not require dialysis prior to implant, or a rise in serum creatinine of
greater than 2.5 mg/dL or greater than two times baseline.
Bleeding was defined as blood loss requiring a blood transfusion or
surgical exploration for resolution. Vascular complications requiring sur-
gical repair were defined as a pseudoaneurysm, an arteriovenous fistula,
a vessel dissection/perforation, or an access site thrombosis that
requires surgical intervention. Hematoma was defined as any palpable
swelling ≥5 cm in maximum diameter at vascular access site diagnosed
by ultrasound, computerized tomography (CT) scan, or palpation at the
skin level. Hemolysis was defined by abnormal plasma free hemoglobin
values greater than 40 mg/dL or presence of hematuria.
2.3 | Device
Impella 2.5 and CP devices (Abiomed Inc., Danvers, MA) are FDA-
approved for up to 6 days for cardiogenic shock and up to 6 hr for
high risk coronary interventions. Impella 2.5 and CP provide direct
cardiac pressure and volume unloading of the left ventricle and
antegrade flow in the thoracic aorta of up to 2.5 and 4.0 L/min,
respectively. The catheter-based device is typically inserted through a
peripheral access using a single arterial access of 13Fr and 14Fr,
respectively. From a pathophysiologic standpoint, unloading leads to
decreased wall stress of the left ventricle by reducing left ventricular
end-diastolic volume, pressure, and oxygen demand.15–18 In addition,
the pump flow from the Impella increases the mean arterial pressure,
diastolic pressure, and cardiac output. The result is enhanced coronary
and end organ perfusion.16
2.4 | Data collection
Data were abstracted retrospectively from the medical record to a
standard electronic case report form by the sites' study coordinators
who were centrally trained. Information was collected on patient's
demographic characteristics, medical history, clinical presentation,
hemodynamic, echocardiographic, angiographic characteristics, and
treatment during hospitalization, hospital discharge status, and follow
up status when available at the time of data collection. Data were
monitored against source documentation to maximize accuracy. All
patients reported in the registry that met the listed inclusion criteria
of protected PCI were included in the current analysis without pre-
selection of patients or sites.
2.5 | Statistical analysis
Data are expressed as mean ± SD or median as appropriate. Qualita-
tive data are presented as proportion. Categorical variables were
tested using Pearson's Chi-square test for contingency tables or
Fisher Exact test, as appropriate. Continuous variables were analyzed
by an independent t-test or paired t-test. All statistical tests and/or
confidence intervals, as appropriate, were performed with a two-sided
p value of .05. Kaplan–Meier estimates of the cumulative incidence of
MACCE and of survival through 30 days were performed, and a Log-
rank test was used to compare the curves between the two groups at
this time point. Statistical analysis was performed using SAS Software
v10 (SAS Institute Inc., Cary, NC).
3 | RESULTS
A total of 1,053 consecutive patients in the cVAD registry (mean age
69.66 ± 11.37, African American 17.83%) underwent high-risk PCI
assisted with MCS using Impella 2.5 or CP. Baseline characteristics
stratified by sex are presented in Table 1. Of the 1,053 patients,
261 (24.79%) were females and 792 (75.21%) were males. Both gen-
ders were similar in terms of prevalence of hypertension, stroke, exis-
ting heart failure, prior myocardial infarction (MI), and prior PCI.
Women were older (72.05 ± 11.66 vs. 68.87 ± 11.17, p < .001), and
had a lower body surface area (BSA) (1.80 vs. 2.02, p < .001). Females
also had a higher prevalence of diabetes (59.3 vs. 49.04%, p of .005),
renal insufficiency (35.41 vs. 27.39%, p of .018), peripheral vascular
disease (31.89 vs. 25.39%, p of .05), lower hemoglobin (11.00 ± 1.73
vs. 13.08 ± 9.07, p < .001) and valvular disease (18.02 vs. 11.44%,
p < .001). In contrast, females had a lower prevalence of tobacco use
(29.03 vs. 40.18%, p of .002), arrhythmia (22.22 vs. 33.38%, p < .001)
and prior CABG (19.07 vs. 32.70%, p < .001) (Table 1).
Despite having a higher left ventricular ejection fraction on pre-
sentation (33.18 ± 17.75 vs. 28.04 ± 15.37, p < .001), females overall
were at greater risk of death as indicated by Society of Thoracic Sur-
geons (STS) mortality scores (8.21 ± 8.21 vs. 5.04 ± 5.97, p < .001)
and morbidity scores (34.72 ± 17.75 vs. 27.85 ± 16.74, p < .001)
(Table 1). Women were more likely to be seen by the surgical team
(51.57 vs. 39.43%, p < .001) and to be considered for CABG (38.89
vs. 29.11%, p of .005).
Impella 2.5 was more used than Impella CP. Impella 2.5 was used in
94% of cases for females and 89% of cases for males. Less than one
third of the patients presented with an acute MI and the majority of
them had non-ST segment elevation myocardial infarctions (NSTEMI)
(87%) with no difference between females and males (Table 2). Only
26.30% of the patients were transfers from a different hospital. None
of the patient had cardiogenic shock on presentation as this was one of
the exclusion criteria. However, a total of 71% females and 70% of
males presented with New York Heart Association (NYHA) Class
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TABLE 1 Baseline characteristics stratified by sex
Characteristics Total (N = 1,053) Female (N = 261) Male (N = 792) p-value
Age, mean ± SD(N) 69.66 ± 11.37 72.05 ± 11.66 68.87 ± 11.17 <.001
Asian 2.48% 2.31% 2.53% .99
African American 17.83% 25.77% 15.21% <.001
Caucasian 69.49% 61.92% 71.99% .003
BSA (m2), mean ± SD(N) 1.97 ± 0.26 1.80 ± 0.25 2.02 ± 0.24 <.001
BMI (kg/m2), mean ± SD(N) 28.99 ± 7.06 30.21 ± 8.26 28.59 ± 6.57 .005
Hyperlipidemia 74.50% 71.37% 75.51% .187
Hypertension 90.10% 93.10% 89.11% .072
Diabetes mellitus 51.59% 59.30% 49.04% .005
CAD 85.50% 83.04% 86.27% .233
Smoker 37.46% 29.03% 40.18% .002
Stroke/TIA 5.82% 6.42% 5.63% .623
Cerebrovascular disease 18.11% 19.84% 17.54% .450
Renal insufficiency 29.39% 35.41% 27.39% .018
Dialysis 26.13% 34.12% 22.77% .056
Liver insufficiency 2.78% 3.21% 2.64% .658
COPD 22.64% 22.31% 22.75% .931
Arrhythmia 30.63% 22.22% 33.38% <.001
PVD 27.01% 31.89% 25.39% .050
CHF 54.91% 51.12% 56.10% .217
NYHA class
I 7.49% 8.97% 7.03% .623
II 19.76% 17.95% 20.31% .746
III 44.61% 35.90% 47.27% .091
IV 28.14% 37.18% 25.39% .046
III/IV 72.75% 73.08% 72.66% .99
Valvular disease 13.01% 18.02% 11.44% .016
Cardiomyopathy 42.38% 33.78% 45.07% .003
Prior MI 46.93% 45.82% 47.29% .716
Hours between MI onset and start of PCI, mean ± SD(N) 166.8 ± 246.0 230.6 ± 42.2 143.6 ± 132.7 .252
Prior AICD/pacer implanted 22.63% 15.35% 25.00% .001
Prior PCI 47.04% 41.67% 48.78% .050
Prior CABG 29.34% 19.07% 32.70% <.001
Surgical consultation was requested 42.43% 51.57% 39.43% <.001
CABG was considered for treatment 31.51% 38.89% 29.11% .005
LVEF (%), mean ± SD(N) 29.3 ± 15.8 33.18 ± 16.68 28.04 ± 15.37 <.001
STS mortality score, mean ± SD(N) 5.8 ± 6.7 8.21 ± 8.21 5.04 ± 5.97 <.001
STS morbidity score, mean ± SD(N) 29.59 ± 17.25 34.72 ± 17.75 27.85 ± 16.74 <.001
Hgb (g/dL), mean ± SD(N) 12.56 ± 7.95 11.00 ± 1.73 13.08 ± 9.07 <.001
Platelet count (103/μl), mean ± SD(N) 200.6 ± 69.8 218.77 ± 78.17 194.61 ± 65.7 <.001
Creatinine (mg/dL), mean ± SD(N) 1.49 ± 1.1 1.53 ± 1.36 1.48 ± 1.10 .570
GFR (ml min−1 m−2), mean ± SD(N) 57.53 ± 27.5 46.92 ± 23.27 61.30 ± 27.99 <.001
AST (U/L), mean ± SD(N) 46.94 ± 72.0 51.81 ± 87.33 45.00 ± 65.01 .484
ALT (U/L), mean ± SD(N) 41.50 ± 62.9 37.36 ± 55.84 43.10 ± 65.56 .444
Abbreviations: AICD, automated implantable cardioverter defibrillator; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass
index; BSA, body surface area; CABG, coronary artery bypass grafting; CAD, coronary artery disease; CHF, congestive heart failure; COPD, chronic
obstructive pulmonary disease; GFR, glomerular filtration rate; Hgb, hemoglobin; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NYHA,
New York Heart Association; PCI, percutaneous coronary intervention; PVD, peripheral vascular disease; STS, society of thoracic surgery; TIA, transient
ischemic attached.
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III/IV. After the procedure, 50% of females and 55% males of had
NYHA Class III/IV. Females had high coronary artery disease burden
compared to males (number of vessels 1.90 ± 0.71 vs. 1.69 ± 0.77,
p < .001). Overall, there was a statistically significant difference in the
number of vessels treated between the genders. Specifically, males had
a higher rate of 1 vessel treatment and females had a higher rate of
2 vessel treatment. There was no statistical significance in the rate of
3 vessel treatment. Females had similar rates of left main disease com-
pared to males (18.67 vs. 15.64% p of .056). Consistent with the higher
CABG rates in males, there was higher occurrence of graft intervention.
The majority of the coronary lesions were in proximal segments with
no difference between females and males. Impella access sites, pump
flow and pressure levels were similar between groups (Table 2).
Right heart catheterization data were available in a small subset of
patients. The data suggest a disparity in pulmonary artery (PA) catheter
placement between females and males: 24% of females and 75% of
males. Baseline hemodynamic characteristics prior to device placement
were similar for both females and males prior to insertion and initiation
of Impella device (Table 3). Women had lower diastolic blood pressure
compared to men and slightly lower cardiac output.
Survival rates at the time of discharge were comparable for
females and males (95.02 vs. 96.84%, p of 0.18). Myocardial infarction
TABLE 2 Admission and procedural characteristics stratified by sex
Characteristics Total (N = 1,053) Female (N = 261) Male (N = 792) p-value
Patient was transferred from another hospital 26.30% 31.02% 24.73% .055
Patient was supported with an IABP prior to Impella support 4.67% 6.76% 4.01% .101
Acute myocardial infarction 28.80% 35.63% 26.55% .006
STEMI 13.10% 18.89% 10.50% .060
NSTEMI 86.90% 81.11% 89.50% .060
Number of diseased vessels (≥50% stenosis), mean ± SD(N) 1.74 ± 0.76 1.90 ± 0.71 1.69 ± 0.77 <.001
Number of vessels treated, mean ± SD(N) 1.58 ± 0.71 1.71 ± 0.67 1.54 ± 0.72 <.001
Patients with 1 vessel treated 38.43% 29.34% 41.47% <.001
Patients with 2 vessels treated 48.21% 58.30% 44.83% <.001
Patients with 3 vessels treated 7.84% 8.49% 7.62% .689
SVG intervention (at least one SVG lesion attempted) 7.94% 3.47% 9.43% .001
Number of lesions treated, mean ± SD(N) 1.71 ± 0.77 1.77 ± 0.81 1.69 ± 0.75 .172
Number of stents used, mean ± SD(N) 2.20 ± 1.17 2.29 ± 1.2 2.18 ± 1.15 .187
Impella access
Femoral 99.56% 99.54% 99.56% .99
Subclavian or axillary 0.44% 0.46% 0.44% .99
Impella pump flow (L/min), mean ± SD(N) 2.23 ± 0.81 2.16 ± 0.41 2.26 ± 0.9 .051
Vessel location
LAD 35.50% 35.42% 35.53% .965
Left Main 16.43% 18.67% 15.64% .056
LCx 27.82% 27.75% 27.85% .99
RCA 15.97% 16.50% 15.78% .650
Graft 4.28% 1.66% 5.20% <.001
LIMA 0.47% 0.13% 0.59% .133
SVG 3.81% 1.53% 4.61% <.001
Lesion location
Proximal 45.51% 44.02% 46.07% .368
Mid 27.81% 27.99% 27.74% .920
Distal 18.50% 18.51% 18.49% .99
Ostial 8.19% 9.48% 7.70% .164
TIMI flow 0/1 pre PCI 9.02% 7.50% 9.49% .292
TIMI flow 0/1 post PCI 1.76% 1.40% 1.89% .558
Abbreviations: LAD, left anterior descending; LCx, left circumflex crater; LIMA, left internal mammary artery; NSTEMI, Non-ST elevation myocardial
infarction; PCI, percutaneous coronary intervention; RCA, right coronary artery; SD, standard deviation; STEMI, ST-elevation myocardial infarction; SVG,
saphenous vein graft; TIMI, thrombolysis in myocardial infarction.
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(1.15 vs. 0.76%, p of .70), need for repeat revascularization (0.77
vs. 0.63%, p of .69), and stroke (0.00 vs. 0.13%, p of .99) were infre-
quent and similar in females and males (Table 4). There were no differ-
ences in terms of vascular complications, cardiac arrhythmias, acute
kidney injury, or dialysis requirements between two groups. However,
females had higher rate of bleeding requiring blood transfusion com-
pared to males (9.5 vs. 5.3%, p of .019). In addition, survival rate and
MACCE to 30 days was comparable in both groups (93 vs. 94%, p of
.441, 9.8 vs. 9.3%, p of .434, respectively) (Figures 1 and 2). Ejection
fraction improved in both males and females at the time of discharge
(26.59 to 31.40% and 30.75 to 36.05%, respectively, p < .0001). Specifi-
cally, both females (mean difference 5.30, 95% CI 9.74 to 0.87, p < .001)
and males (mean difference 4.8, 95% CI 7.40 to 2.21, p < .001) improved
their left ventricular ejection fraction (LVEF) (Table 5).
4 | DISCUSSION
We performed a retrospective analysis of a multicenter prospective
registry. Based on our study, the differences between females and
TABLE 3 Baseline Hemodynamics Prior to Impella Placement
HRPCI (N = 1,053) Females (N = 261) Males (N = 792) p-value
HR (bpm), mean ± SD(N) 72.93 ± 17.00 73.29 ± 16.89 72.81 ± 17.05 .696
Systolic blood pressure (mmHg), mean ± SD(N) 122.73 ± 25.01 125.48 ± 27.26 121.81 ± 24.16 .055
Diastolic blood pressure (mmHg), mean ± SD(N) 69.40 ± 14.94 64.94 ± 15.40 70.88 ± 14.50 <.001
Mean arterial pressure (mmHg), mean ± SD(N) 87.57 ± 16.89 85.53 ± 18.45 88.25 ± 16.29 .037
Cardiac index (L min−1 m−2), mean ± SD(N) 2.24 ± 0.75 2.11 ± 0.80 2.27 ± 0.73 .293
Cardiac output (L/min), mean ± SD(N) 4.41 ± 1.50 3.64 ± 1.30 4.63 ± 1.49 .001
PCWP (mmHg), mean ± SD(N) 20.90 ± 9.96 21.58 ± 10.79 20.68 ± 9.71 .624
PAP (mmHg), mean ± SD(N) 24.15 ± 12.24 23.55 ± 12.92 24.35 ± 12.05 .709
Abbreviations: HR, heart rate; PCWP, pulmonary capillary wedge pressure; PAP, peripheral artery pressure; SD, standard deviation.
TABLE 4 In-hospital adverse events stratified by sex
Adverse events Total (N = 1,053) (%) Females (N = 261) (%) Males (N = 792) (%) p-value
Death 3.61 4.98 3.16 .181
Myocardial infarction 0.85 1.15 0.76 .698
CVA/stroke 0.09 0.00 0.13 .99
TIA 0.00 0.00 0.00 –
Valve injury 0.00 0.00 0.00 –
Acute renal dysfunction 4.65 6.51 4.04 .126
Revascularization 0.66 0.77 0.63 .686
Hemolysis 0.00 0.00 0.00 –
Acute hepatic failure 0.19 0.38 0.13 .434
Bleeding requiring surgery 0.66 0.77 0.63 .686
Bleeding requiring transfusion 6.36 9.58 5.30 .019
Device malfunction 0.09 0.00 0.13 .99
Hematoma 3.80 4.60 3.54 .456
Vascular complication requiring surgery 1.23 2.30 0.88 .100
Vascular complication without surgery 2.18 2.68 2.02 .475
Aortic valve regurgitation > = 2 grades from baseline 0.00 0.00 0.00 –
Need for cardiac, thoracic or abdominal vascular operation or
femoral artery bypass graft (not isolated femoral artery)
0.28 0.38 0.25 .575
Infection 2.09 3.07 1.77 .215
Cardiopulmonary resuscitation or ventricular arrhythmia 3.61 4.21 3.41 .567
Failure to achieve angiographic success
(as residual stenosis <30% after stent implant)
0.38 0.77 0.25 .258
Abbreviations: CVA, cerebrovascular accidence; TIA, transient ischemic attacked.
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males in the treatment of high-risk PCI from the cVAD Registry are1;
symptomatic females with complex high-risk coronary disease have
higher comorbidities and are at greater risk of death with CABG as indi-
cated by STS score compared to males.2 Females were equally likely as
males to survive to hospital discharge after high-risk PCI with MCS sup-
port despite having higher STS mortality risk scores.3 Myocardial infarc-
tion, stroke, AKI, repeat revascularization, and vascular complications
rates were also similar in both sexes.4 Females were equally likely to
develop hematoma and bleeding as males, they required more blood
transfusions compared to their male counterparts.
The use of MCS for high-risk PCI has increased in recent years.19
This is due, in part, to patient demographic changes including increased
comorbidities, older age, and greater impairments of LV systolic
function of patients referred to the cath lab for coronary intervention.
In addition, technological improvements in the Impella platform with
enhanced ease of use and increasing operator skill and familiarity with
Impella and protected PCI have also contributed to increased utiliza-
tion. The randomized controlled clinical trial PROTECT II compared
Impella 2.5 with intra-aortic balloon pump (IABP) during high-risk PCI
and showed that the use of the Impella 2.5 is not superior to IABP in
reducing adverse events at 30 and 90 days. Although there was no dif-
ference in in-hospital death, stroke, myocardial infarction, or the com-
posite of death/stroke/MI between Impella 2.5 and IABP, fewer
irreversible MACCE of death/stroke/ MI (7.0 vs. 12.9%, p = .042) and
of death/stroke/ MI/repeat revascularization (9.8 vs. 18.6%, p = .009)
occurred after hospital discharge in the Impella 2.5 arm in comparison
with the IABP arm. Furthermore, it showed superior hemodynamic sup-
port with Impella allowing more vessels to be treated, more stents used,
and more lesion modification with atherectomy.7 The ability to perform
high-risk PCI safely has been attributed to decreasing left ventricular
wall stress from unloading the left ventricle, reducing left ventricular
end-diastolic volume, and lowering ventricular pressure and oxygen
demand.15–18 Furthermore, Impella use during PCI has been shown to
enhance coronary and end organ perfusion and may reduce the risk of
AKI.16,20 These findings and others have led to increased utilization of
MCS, especially Impella, during CHIP cases.
Complete revascularization of coronary disease has been shown
to improve overall outcomes when compared with incomplete revas-
cularization. Both females and males, had better outcomes in terms of
mortality, MACE and overall complications when complete revascular-
ization was performed.21–24 In addition, 90-day follow-up data from
the PROTECT II trial showed a significant decrease in major adverse
events (37 vs. 49% p of .014) and major adverse cardiac and cerebral
events (22 vs. 31%, p of .034) in the Impella group, driven by more
complete revascularization. In our study, both females and males had
similar in-hospital mortality, stroke, MI and need for revascularization
regardless of the number of vessels and lesions treated. Myocardial
ischemia associated with treatment of left main coronary disease and
multi-vessel PCI are better tolerated with circulatory support. Similar
findings were reported in a recent study by Doshi et al. They analyzed
gender differences by looking at short-term survival and in-hospital
outcomes in those undergoing Impella assisted PCI in the setting of
cardiogenic shock. They showed that men and women who had com-
plete revascularization with Impella support had no sex difference in
clinical outcomes. There was no difference in in-hospital mortality or
F IGURE 1 Freedom from death at 30 days
F IGURE 2 Freedom from major adverse cardiac events (MACE) at
30 days
TABLE 5 Ejection fraction (%) at baseline and at longest follow-up
All patients At baseline(N = 1,053 patients) At longest follow-up(N = 1,053 patients) Difference [95% CI] p-value
LVEF (%) mean ± SD (N) 27.70 ± 14.82 32.64 ± 15.45 −4.94[−7.19, −2.69] <.0001
Males (N = 792)
LVEF (%), mean ± SD (N) 26.59 ± 14.51 31.40 ± 15.32 −4.80[−7.40, −2.21] <.0001
Females (N = 261 patients)
LVEF (%), mean ± SD (N) 30.75 ± 15.32 36.05 ± 15.38 −5.30[−9.74,−0.86] <.0001
Abbreviations: CI, confidence interval; LVEF, left ventricular ejection fraction; SD, standard deviation.
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30-day survival rates Secondary outcomes such as major adverse car-
diac events, dialysis requirement, bleeding within 72 hr, blood transfu-
sion, dysrhythmia were similar in both cohorts.25
Complete revascularization is often achieved with CABG surgery
and has been shown to be associated with long-term mortality bene-
fits.26,27 However, CHIP population patients are often turned down
for surgical intervention given the severity of their CAD with low LV
function and comorbidities that put the patient at high or extreme
surgical risk. In addition, patients may decline surgery because of
personal preference. In this study, there were more CABG consulta-
tions for females than males (51.57 vs. 39.43%, p < .001) which may
indicate higher CAD burden or coronary lesion complexity compared
to males. However, more female patients were deemed ineligible for
CABG surgery than males due to concomitant comorbidities that
precluded them from CABG (18.62 vs. 9.59%, p of .002). Further-
more, females had on average higher STS mortality scores and higher
STS morbidity scores, making them poor surgical candidates. Based
on these findings, protected PCI represents a useful alternative to
CABG based on in-hospital adverse events. Similarly, in another trial,
complex multivessel CAD patients who underwent protected PCI
with the Impella 2.5 device experienced similar in-hospital major
adverse cardiac and cerebrovascular event rates when compared to
CABG. However, patients undergoing CABG experienced signifi-
cantly more peri-procedural additional adverse events (28.6 vs. 3.8%;
p < .05).3 In our cohort, women had higher rates of renal insuffi-
ciency than men at baseline and despite this, the clinical outcome
including worsening renal failure or renal failure requiring dialysis
was similar in females and males. This finding is consistent with a
study by Flaherty et al. who examined the impact of Impella MCS on
renal function after high-risk PCI. This study demonstrated that
MCS with Impella was associated with a significant reduction in AKI
despite the presence of CKD or severely reduced left ventricular
ejection fraction.20
Previous studies have shown that females with acute coronary
syndrome are treated less aggressively than males despite presenting
with higher risk characteristics and having higher in-hospital risk.10 In
the PROTECT II trial, only 20% were females, which is an underrepre-
sentation in the overall population undergoing complex high-risk PCI.
In our study, females had higher rate of comorbidities such as diabe-
tes, renal insufficiency, and PVD that confer greater risk of adverse
events during high-risk PCI. Yet, females were found to have equal
survival and clinical outcomes to hospital discharge. Of note, a prior
study among patients with cardiogenic shock by Joseph et al., demon-
strated that female patients derived a greater benefit from Impella
supported high-risk PCI.28
Females are known to have higher risk of access site complications
and the use of transradial route in percutaneous coronary intervention
has been shown to reduce access site bleeding.29 Although females had
lower baseline hemoglobin and experienced more bleeding that
required blood transfusion they were not at increased risk of vascular
complications compared with males. However, the difference in bleed-
ing events was not significant after adjusting for baseline hemoglobin
levels suggesting that patient baseline condition/anemia was mainly
responsible. Continued advances in best practices for safe femoral
access may further improve this hazard for both females and males.
5 | LIMITATIONS
Our study using the cVAD registry study has several limitations. The
data analyzed were retrospectively collected and included Impella
treated patients only. Causality regarding the impact of Impella on
outcomes cannot be inferred, and residual confounding factors cannot
be excluded. Second, women constituted only 24.79% of our study
population. Consequently, this could be underpowered to detect sex
differences in clinical outcomes. Therefore, this study should be used
to generate further prospective data to elucidate whether sex-related
differences exist in a larger sample size of protected PCI patients.
However, this study included all comers with no exclusion criteria at
participating sites, and all patients were treated with Impella 2.5 or
Impella CP. Therefore, this study reflects real-world practice.
6 | CONCLUSION
Only 25% of the patients referred for high risk PCI are females, which
suggest that females may encounter barriers to access to highly spe-
cialized medical care. Also, despite being older and sicker, females had
favorable outcomes after high risk PCI that were not different com-
pared to males.
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